3fcb: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:3fcb.png|left|200px]] | |||
[[Image:3fcb. | |||
{{STRUCTURE_3fcb| PDB=3fcb | SCENE= }} | {{STRUCTURE_3fcb| PDB=3fcb | SCENE= }} | ||
===Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOH=== | ===Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOH=== | ||
{{ABSTRACT_PUBMED_19125186}} | {{ABSTRACT_PUBMED_19125186}} | ||
==About this Structure== | ==About this Structure== | ||
[[3fcb]] is a 2 chain structure of [[Transthyretin]] with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3FCB OCA]. | |||
==See Also== | |||
*[[Transthyretin|Transthyretin]] | |||
==Reference== | ==Reference== | ||
<ref group="xtra">PMID: | <ref group="xtra">PMID:019125186</ref><references group="xtra"/> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Damas, A M.]] | [[Category: Damas, A M.]] | ||
| Line 31: | Line 22: | ||
[[Category: Inhibitor]] | [[Category: Inhibitor]] | ||
[[Category: Iodine]] | [[Category: Iodine]] | ||
[[Category: Polyneuropathy]] | [[Category: Polyneuropathy]] | ||
[[Category: Retinol-binding]] | [[Category: Retinol-binding]] | ||
[[Category: Secreted]] | [[Category: Secreted]] | ||
[[Category: Transthyretin]] | [[Category: Transthyretin]] | ||
Revision as of 03:42, 27 July 2012
Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOH
Template:ABSTRACT PUBMED 19125186
About this Structure
3fcb is a 2 chain structure of Transthyretin with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See Also
Reference
- Mairal T, Nieto J, Pinto M, Almeida MR, Gales L, Ballesteros A, Barluenga J, Perez JJ, Vazquez JT, Centeno NB, Saraiva MJ, Damas AM, Planas A, Arsequell G, Valencia G. Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS ONE. 2009;4(1):e4124. Epub 2009 Jan 6. PMID:19125186 doi:10.1371/journal.pone.0004124